Trump's Pharma Pact Delivers Unprecedented Drug Price Drops
President Donald Trump made headlines with landmark pharmaceutical agreements, proclaiming them 'history's greatest cuts in drug prices.' From the White House podium, he detailed how major firms will...
President Donald Trump made headlines with landmark pharmaceutical agreements, proclaiming them 'history's greatest cuts in drug prices.' From the White House podium, he detailed how major firms will cap U.S. costs at global minimums, easing burdens on patients nationwide. Regeneron led the charge, pledging 'most favored nation' pricing for revolutionary savings. These 17 industry leaders, holding 80% of branded drug sales, commit to passing on the lowest worldwide rates to American buyers. Trump decried decades of exploitation, where Americans paid premiums to bankroll foreign discounts. RFK Jr., Health and Human Services Secretary, framed it as ending the 'looting machine,' spotlighting America's outsized 75% profit share from 4.2% of world population. CMS Administrator Mehmet Oz stressed accessibility: one-third of citizens ration or skip drugs due to costs. Highlights include a cholesterol med slashed from $537 to $225, and obesity treatment from $1,350 to $199 monthly. Voluntarily on board, Regeneron CEO Leonard Schleifer hailed it as progress. Breakthrough news: a gene therapy for rare deafness, free initially for kids. Executive George Yancopoulos shared Travis's story—hearing his mother's voice after treatment. Parent Sierra Smith called her son's outcome 'miraculous,' now able to hear fully. Howard Lutnick, Commerce Secretary, projected $448 billion in reshored manufacturing. Spanning 86% of the market with more negotiations, this heralds a new era of equitable drug pricing.